DOCSLIB.ORG

Supermuc Enables Major Finding in Personalised Medicine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supermuc Enables Major Finding in Personalised Medicine PRESS RELEASE 03/2016 SuperMUC Enables Major Finding in Personalised Medicine Berlin/Germany, June 20, 2016 – A European research team headed by Professor Peter Coveney, Centre for Computational Science at the University College London (UCL), achieved a major success in the field of personalised medicine: Peter Coveney and his team were able to prove that by using genomic data of individual patients they are able to predict whether a specific standard drug for the treatment of breast cancer will help or not. The findings were achieved during an “Extreme Scaling Workshop” in which the researchers had the entire supercomputer SuperMUC of GCS member Leibniz Supercomputing Centre (LRZ) in Garching near Munich with all its resources at their disposal to generate and plough through a vast amount of data looking for further clues into how drugs work. For a patient suffering from breast cancer, several standard drugs are at the doctor's disposal today. The effect of the drug is, however, depending on the individual patient's genomic fingerprint. Which means: While a certain drug treatment would work for one person it may not for the other. Clearly, it would increase the efficiency of the treatment dramatically if a physician had the chance to match - within a reasonable time frame - the analysed predispositions written into the genome of the individual patient with the behaviour of certain drugs. It would put the physician in the position to choose a product tailored to the patient. At this point in time, calculations of these dimensions can only be performed on the largest supercomputers available. Considerable progress has been made in the field of personalised medicine in recent years, and supercomputers will play a major role in its further advancement. Peter Coveney holds a chair for Physical Chemistry. He investigates why a range of drugs exhibit varying degrees of binding to proteins within patients with specific mutations. Coveney knows about the details of the proteins interacting with the drugs and potential drugs. With the help of high performance computing (HPC) systems, this interaction can be computed and understood using state-of-the-art simulation technologies. Depending on the strength of this interaction, one can judge whether the drug will be effective or not. Mutations change the sequence of amino acids, and as a consequence the structure of the protein is modified and with it its interaction with the drug. It is precisely this interaction, that Peter Coveney is able to compute very rapidly and accurately leveraging the computing power of HPC system SuperMUC which delivers a peak performance of 6.8 Petaflops. The existing very detailed knowledge of the molecules, a knowledge collected over decades of experimental and theoretical research, allows for very accurate scientific computations -- if the necessary gigantic compute resources, required for number-crunching jobs of this type and magnitude, are available. Which is what happened to the researchers by having access to all of the 250,000 compute cores of the LRZ HPC system in the framework of an Extreme Scaling Workshop. These workshops are held regularly at the GCS member centres with the aim to improve the computational efficiency of HPC applications by expanding their parallel scalability across the hundreds of thousands of compute cores of the GCS supercomputers. Gauss Centre for Supercomputing Regina Weigand (GCS Public Relations) Alexanderplatz 1 – D-10178 Berlin (Germany) – www.gauss-centre.eu ++49 (0)711 685-87261 – [email protected] Page 2 of GCS Press Release 03/2016 “We were given the whole machine for an uninterrupted period of 37 hours--that is equivalent to something like a quarter of a million people beavering away on everyday personal computers for 37 hours--and we generated about 5 terabytes of data. We achieved all our objectives and more because the jobs in the workflow ran much faster than anticipated. Preliminary analysis indicates that the simulations will provide insight into how the two most common mutations responsible for acquired resistance to major anti-breast cancer drugs interfere with drug binding,” stated Prof Coveney. The purpose of this project was to demonstrate that, within just a few hours, scientists can work out the way that candidate as well as existing drugs will act on a target in the body - a protein. “Fifty drugs and candidate drugs were studied to determine how they bind with protein targets in a range of disease cases, in order to rank their potency for drug development and for drug selection in clinical decision making,” Coveney explained. If this approach evolved into a sustained procedure, it would mark an important advance for personalised medicine, that is medicine designed with one specific patient in mind so that it works efficiently, and without side effects. “It is taking far too long and costing far too much to discover new drugs by conventional experimental means; computer-based methods are the way forward,” said Prof Coveney. “Now that we can read the genetic makeup of a person relatively cheaply we should be able to develop and target many more drugs to specific individuals,” he explained. “Most existing drugs are not effective against large swathes of the general population. In such clinical contexts, decisions regarding matching a drug to a patient will need to be taken within hours to effectively treat individuals and that is what we are trying to achieve.” The research activities were carried out in the framework of COMPAT, an EU funded research project in which eleven European partners are involved including LRZ and University College London. COMPAT defines itself “as a science driven project. The urgent need to push the science forward, and stay at the forefront in simulation driven science and engineering is our major motivation.” Because of the very challenging requirements of the numerical computations, the application software was selected as a candidate for the Extreme Scaling activities at the GCS centre LRZ. “We are very proud that our SuperMUC system proved to be extremely useful in the research activities on personalised medicine,” says Prof. Arndt Bode, Chairman of the Board of Directors of LRZ. And Prof. Dieter Kranzlmüller, Director of LRZ and project partner in COMPAT, adds: “Supercomputing technologies play a key role in almost all fields of science, and looking at the exciting results of this project, life science can't go without it either. As these new findings substantiate, supercomputing is an indispensable tool to boost the advancement of personalised medicine research, too, and thus will help to cure disease and improve human lives.” About GCS: The Gauss Centre for Supercomputing (GCS) combines the three national supercom- puting centres HLRS (High Performance Computing Center Stuttgart), JSC (Jülich Supercomputing Centre), and LRZ (Leibniz Supercomputing Centre, Garching near Munich) into Germany’s Tier-0 supercomputing institution. Concertedly, the three centres provide the largest and most powerful supercomputing infrastructure in all of Europe to serve a wide range of industrial and research activities in various disciplines. They also provide top-class training and education for the national as well as the European High Performance Computing (HPC) community. GCS is the German member of PRACE (Partnership for Advanced Computing in Europe), an international non-profit association consisting of 25 member countries, whose representative organizations create a pan-European supercomputing infrastructure, providing access to computing and data management resources and services for large- scale scientific and engineering applications at the highest performance level. GCS is jointly funded by the German Federal Ministry of Education and Research and the federal states of Baden-Württemberg, Bavaria and North Rhine-Westphalia. It has its headquarters in Berlin/Germany. (www.gauss-centre.eu) Gauss Centre for Supercomputing Regina Weigand (GCS Public Relations) Alexanderplatz 1 – D-10178 Berlin (Germany) – www.gauss-centre.eu ++49 (0)711 685-87261 – [email protected] Page 3 of GCS Press Release 03/2016 HPC System SuperMUC of LRZ Garching/Munich, (c) Johannes Naumann for LRZ Gauss Centre for Supercomputing Regina Weigand (GCS Public Relations) Alexanderplatz 1 – D-10178 Berlin (Germany) – www.gauss-centre.eu ++49 (0)711 685-87261 – [email protected] .
Load more

Recommended publications
  • Curriculum Vitae Bruce M
    Curriculum Vitae Bruce M. Boghosian Professor and Chair of Mathematics Tufts University 211 Bromfield-Pearson Hall, Tufts University Medford, Massachusetts 02155, U.S.A. [email protected] (617) 627-3054 (direct), (617) 627-3966 (fax) Employment History • Tufts University, Medford, MA: Professor and Chair, Department of Mathematics (2000 – present, promoted to rank of Professor in 2003, promoted to Chair in 2006); Adjunct Professor, Department of Computer Science (2003 – present). • Boston University, Boston, MA: Research Associate Professor, Center for Computational Science and Depart- ment of Physics (1994 – 2003). • Thinking Machines Corporation, Cambridge, MA: Senior Scientist, Mathematical Sciences Research Group (1986 – 1994). • Lawrence Livermore National Laboratory, Livermore, CA: Physicist, Plasma Theory Group (1978 – 1986). Visiting Positions • Ecole´ Normale Superieure´ , Paris, France: Visiting Researcher (7 April – 7 May 2008). • Peking University, Beijing, China: Visiting Professor, School of Engineering, gave half-semester course enti- tled “Topological Fluid Dynamics” (5 November – 12 December 2007). • University College London: EPSRC Visiting Fellow, Centre for Computational Science, Department of Chem- istry (2002-present). • University of California, Berkeley: Visiting Professor, Department of Physics (1996 – 1997). • International Centre for Theoretical Physics, Trieste, Italy: Visiting Scientist, Condensed Matter Division (Summer, 1996). • Schlumberger Cambridge Research Centre, Cambridge, UK: Consultant (1994
    [Show full text]
  • Author List Poster # Day Title
    CSE19 Poster Board Assignments Alphabetical by Presenter Author List Poster # Day Session Title (italics indicates presenter) Joshua R. Abrams , University of Arizona, U.S.; José Celaya‐Alcalá, Minisymposterium: Analysis of Equity Markets ‐ A Graph Theory Wednesday PP204 Brown University, U.S. 205 Approach Scott Aiton , Donna Calhoun, and Grady B. Wright, Boise State Minisymposterium: A Massively Parallel Solver for Poisson’s Equation Wednesday PP202 University, U.S. 197 on Block Structured Cartesian Grids Nissrine Akkari , Fabien Casenave, and Christian Rey, SAFRAN, Tuesday PP1 Design Exploration of Fuel Injectors Based on Reduced Order Modeling France; Vincent R. Moureau, CORIA, France 1 Said Algarni , King Fahd University of Petroleum and Minerals, Pad\'e Time Stepping Method of Rational Form for Reaction Diffusion Wednesday PP2 Saudi Arabia 2 Equations Jeffery M. Allen , Justin Chang, Francois Usseglio‐Viretta, and Parallel Implementation of a Monolithic Li‐ion Battery Model using Tuesday PP1 Peter Graf, National Renewable Energy Laboratory, U.S. 3 Fenics Matea Alvarado , University of California, Merced, U.S.; Johannes Minisymposterium: Modeling the Chemistry and Hydrodynamics of Wednesday PP201 P. Blaschke, Lawrence Berkeley National Laboratory, U.S. 189 Micro‐swimmers Minisymposterium: Modelling In‐crib Drying of eAr Maize‐ A Case Mercy Amankway, Montana State University 136 Tuesday PP102 Study of Sunyani‐West District Ilona Ambartsumyan , Tan Bui‐Thanh, Omar Ghattas, and Eldar An Edge‐preserving Method for Joint Bayesian Inversion with Non‐ Tuesday PP1 Khattatov, University of Texas at Austin, U.S. 4 Gaussian Priors Sparse Approximate Matrix Multiplication in a Fully Recursive Anton G. Artemov , Uppsala University, Sweden Wednesday PP2 5 Distributed Task‐based Parallel Framework Ibrahim H.
    [Show full text]
  • Final Training and Dissemination Report
    D3.6 Final Training and Dissemination Report Grant agreement no. 675451 CompBioMed Research and Innovation Action H2020-EINFRA-2015-1 Topic: Centres of Excellence for Computing Applications D3.6 Final Training and Dissemination Report Work Package: 3 Due date of deliverable: Month 36 Actual submission date: 30 September 2019 Start date of project: 01 October 2016 Duration: 36 months Lead beneficiary for this deliverable: UvA Contributors: CBK, UCL Project co-funded by the European Commission within the H2020 Programme (2014-2020) Dissemination Level PU Public YES CO Confidential, only for members of the consortium (including the Commission Services) CI Classified, as referred to in Commission Decision 2001/844/EC Disclaimer This document’s contents are not intended to replace consultation of any applicable legal sources or the necessary advice of a legal expert, where appropriate. All information in this document is provided “as is” and no guarantee or warranty is given that the information is fit for any particular purpose. The user, therefore, uses the information at its sole risk and liability. For the avoidance of all doubts, the European Commission has no liability in respect of this document, which is merely representing the authors’ view. PU Page 1 Version 0.3 This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Grant Agreement No 675451 D3.6 Final Training and Dissemination Report Table of Contents 1 Version Log ..........................................................................................................................
    [Show full text]
  • Computational Biomedicine: a Challenge for the 21St Century
    Computational Biomedicine: A Challenge for the 21st Century Peter V Coveney Centre for Computational Science University College London [email protected] NSR-RPI workshop, Monday September 12 2011 Overview • The UCL Centre for Computational Science • Computational Biomedicine Case Studies • Medical Data Storage and Security issues • The Virtual Physiological Human initiative • EU e-infrastructure projects addressing large scale biomedical data processing 2 Centre for Computational Science: “Advancing science through computers” Computation/computational science/computer science is central to modern science. Computational infrastructure both empowers and circumscribes much of what is scientifically achievable. serial P. V. Coveney and R. R. Highfield, Frontiers of Complexity (1995) parallel grid computing Internet Web Grid 3 Centre for Computational Science Advancing science through computers • Computational Science • Algorithms, code development & implementation • High performance, data-intensive & distributed computing • Visualisation & computational steering • Condensed matter physics & chemistry, materials & life sciences • Translational medicine, e-Health & VPH – “data deluge”4 Overview • The UCL Centre for Computational Science • Computational Biomedicine Case Studies • Medical Data Storage and Security issues • The Virtual Physiological Human initiative • EU e-infrastructure projects addressing large scale biomedical data processing 5 Case study I : Grid Enabled Neurosurgical Imaging Using Simulation The GENIUS project aims to model large scale patient specific cerebral blood flow in clinically relevant time frames Objectives: • To study cerebral blood flow using patient-specific image-based models. • To provide insights into the cerebral blood flow & anomalies. • To develop tools and policies by means of which users can better exploit the ability to reserve and co-reserve HPC resources. • To develop interfaces which permit users to easily deploy and monitor simulations across multiple computational resources.
    [Show full text]
  • Applications/Algorithms Roadmapping Activity. First Stage Final Report
    Applications/Algorithms Roadmapping Activity. First Stage Final Report Trefethen, Anne and Higham, Nicholas J. and Duff, Iain and Coveney, Peter 2009 MIMS EPrint: 2009.85 Manchester Institute for Mathematical Sciences School of Mathematics The University of Manchester Reports available from: http://eprints.maths.manchester.ac.uk/ And by contacting: The MIMS Secretary School of Mathematics The University of Manchester Manchester, M13 9PL, UK ISSN 1749-9097 Applications/Algorithms Roadmapping Activity First Stage Final Report June 2009 Contents Preamble ....................................................................................................................................................... 5 Executive Summary ....................................................................................................................................... 6 The Challenge ................................................................................................................................................ 7 Background ................................................................................................................................................... 8 The Changing Face of HPC ........................................................................................................................ 8 Architectural Trends ................................................................................................................................. 9 Relevant activities ....................................................................................................................................
    [Show full text]
  • Japa an W Works Shop
    UK-Japan Workshop: HIGH PERFORMANCE MODELLING OF MULTISCALE BIOMOLECULAR SYSTEMS 17-18 December 2012 sponsored by the British Embassy, Tokyo with support from RIKEN Accommodation In Tokyo Hotel Monterey Hanzomon 23-1 Ichiban-cho, Chiyoda-ku, Tokyo 102-0082 Japan TEL：+81(0)3-3556-7111 / FAX：+81(0)3-3556-0717 http://www.hotelmonterey.co.jp/hanzomon/ How to get to the accommodation of Hotel Monterey Hanzomon from Nariita Airport: http://www.hotelmonterey.co.jp/en/htl/hanzomon/directions.html In Kobe Kobe Portpia Hotel 6 Chome 10-1, Minatoshima Nakamachi, Chuo-ku, Kobe, 650-0046 TEL:+81(0)78-302-1111/FAX: +81(0)78-302-6877 http://www.portopia.co.jp/ Participant List UK Speakers Name Department Affiliation e-mail 1. Dr Dmitry Nerukh Department of Mathematics Aston University [email protected] 2. Dr Sergey Karabasov School of Engineering and Queen Mary [email protected] Materials Science University of London 3. Dr Anton Markesteijn Department of Engineering University of [email protected]. Cambridge uk 4. Prof Peter Coveney Department of Chemistry University College [email protected] London 5. Dr Jochen Blumberger Department of Physics and University College [email protected] Astronomy London 6. Dr Riam Kanso Computational Life and University College [email protected] Medical Sciences Network London [email protected] Japanese Speakers Name Department Affiliation e-mail 1. Dr Makoto Taiji Quantitative Biology Center RIKEN [email protected] (QBiC) 2. Dr Shu Takagi Department of Mechanical University of [email protected] Engineering, School of Tokyo Engineering 3.
    [Show full text]
  • Scalable HPC & AI Infrastructure for COVID-19 Therapeutics
    Scalable HPC & AI Infrastructure for COVID-19 Therapeutics Hyungro Lee∗, Andre Merzky∗, Li Tan{, Mikhail Titov∗, Matteo Turilli∗ Dario Alfey ∗∗, Agastya Bhatiy, Alex Bracex, Austin Clydey, Peter Coveneyy k, Heng Max, Arvind Ramanathanx, Rick Stevensz x, Anda Trifanx yy, Hubertus Van Dam{, Shunzhou Wany, Sean Wilkinsonzz, Shantenu Jha∗ { ∗Rutgers University, {Brookhaven National Laboratory yUniversity College London, zUniversity of Chicago, xArgonne National Laboratory, kUniversity of Amsterdam, ∗∗University of Naples Federico II, yyUniversity of Illinois Urbana-Champaign, zzOak Ridge National Laboratory Abstract—COVID-19 has claimed more 106 lives and resulted These capabilities provide the computational fabric of the in over 40 × 106 infections. There is an urgent need to identify US-DOE National Virtual Biotechnology Laboratory in com- drugs that can inhibit SARS-CoV-2. In response, the DOE bination with resources from the EU Centre of Excellence in recently established the Medical Therapeutics project as part of the National Virtual Biotechnology Laboratory, and tasked Computational Biomedicine. To provide a sense of the impact it with creating the computational infrastructure and methods and scale of operations: these methods and infrastructure are necessary to advance therapeutics development. We discuss being used to screen over 4.2 billion molecules against over innovations in computational infrastructure and methods that a dozen drug targets in SARS-CoV-2. So far, over a 1000 are accelerating and advancing drug design. Specifically, we compounds have been identified and experimentally validated, describe several methods that integrate artificial intelligence and simulation-based approaches, and the design of computational resulting in advanced testing for dozens of hits. The campaign infrastructure to support these methods at scale.
    [Show full text]
  • High- Performance Computing Ground-Breaking Knowledge and Technology
    June 2009 High- performance Computing Ground-breaking knowledge and technology In partnership with: editorial HIGH-PERFORMANCE computing is going to save research oday’s researchers are ‘super-specialists’, far removed from the philosophers and polymaths of the Age of the Enlightenment! T This acute level of specialisation has contributed to the highly technical nature of research, the staggering increase in the number of researchers since 1950 and the exponential rise in the number of publications. The same goes for the research industry: it too has experienced exceptional growth, to the point where it is now highly strategic for a good number of sectors. You’d think this was a sign of good health; however this extreme spe- cialisation has brought about a situation where exchange of informa- tion between researchers is problematic when they don’t belong to the same sub-sub-sub-discipline. Research is now progressing at two different paces. Steadily, with gradual developments, and rapidly, with technological leaps, often carrying over from one field to ano- ther. You can’t reinvent the light bulb by doing research on candles. High-performance computer simulation – this brand new metho- dology which involves reproducing complex three-dimensional, time-dependent phenomena using computers – is a saving grace for our community. Not only does it produce results which would have seemed totally inaccessible thirty years back (some of which are dis- cussed in this special issue) but it has managed to get specialists from various different fields around the same table, reconciling industrial research and university research. A kind of cross-fertilisation is at last taking place between high-performance computing – which hinges on the most recently available ground-breaking fundamental research – and industrial research which is pushing requirements to the extreme limits.
    [Show full text]
  • Upcoming Events Welcome Compbiomed & Bioexcel Free
    Newsletter Issue No. 2 September 2017 Welcome Prof. Peter V Coveney In the three months that have elapsed at the Leibniz Rechenzentrum in Garchug to Prof D Principal Investigator & Comp­ since the publication of our first issue, Kranzlmüller (LRZ), Prof P V Coveney (UCL) and Dr BioMed Coordinator many things have occurred while others H van Vlijmen (Janssen). EPCC at the University of are shortly to take place. We held a tutorial work- Edinburgh, SURFsara in the Netherlands and PRACE shop on 30 May followed on 31 May by a meeting (Partnership for Advanced Computing in Europe) on the calculation of free energies using molecular have started a massive open online course (MOOC) simulation; these were joint meetings with the -Bi in Supercomputing that will be useful for amateurs oExcel Centre of Excellence. Both are reported on and experts alike. We have welcomed a further 5 pages 1 and 3, and together they attracted over one Associate Partners (see pages 2 & 3). hundred people. On 5 July, CompBioMed had its In terms of outreach, we are now preparing for the nine month review at the European Commission in biggest public event we have staged so far — “The Brussels; a short report is provided below (page 2). Virtual Human” at the IMAX theatre within the Lon- Our research, education and training, and outreach don Science Museum, on the evening of 27 Septem- activities have all proceeded apace over the period. ber 2017. All are most welcome to attend. You can In the research area, a new award has recenty been reserve your place by going online at http://my.sci- announced on the Tier-0 supercomputer SuperMUC encemuseum.org.uk/single/SYOS.aspx?p=121972 CompBioMed & BioExcel Free Energy Workshop The Free-Energy Workshop in Lon- ject, who introduced the aim of the meeting to discuss don (31st May 2017) saw more than a state of the art free energy calculation techniques in hundred researchers from across Europe, the context of life and medical science.
    [Show full text]
  • UK Research & Innovation: Science Case for UK Supercomputing
    UK Research & Innovation: Science case for UK Supercomputing Authors: The UKRI Supercomputing Science Case Editorial Board Editor: Mark Wilkinson Editorial Board: Mark Wilkinson (Leicester; Chair), Ewan Birney (EBI), Nilanjan Chakraborty (NCL), Peter Coveney (UCL), David Ford (Swansea), Chris Johnson (EPCC), Bryan Lawrence (NCAS), Mark Parsons (EPCC), Andrew Prescott (Glasgow), David de Roure (Oxford), Debora Sijacki (Cambridge), Nick Trigg (STFC), Beth Wingate (Exeter). DOI:10.5281/zenodo.4985325 21st October 2020 Version history UKRI Supercomputing 18/08/19 Final submitted version Science Case Submitted UKRI Supercomputing 19/08/20 MIW edits of introduction and Science Case Submitted executive summary; Edits to Revised 19.08.20 MCF section 7.5 UKRI Supercomputing 21/09/20 Complete draft incorporating Science Case Submitted all proposed revisions – Revised 21.09.20 circulated to editorial board for final comments. UKRI Supercomputing 21/10/20 Final version of case Science Case Final 21.10.20 submitted to EPSRC for publication. 1 Table of Contents 1 Executive summary 4 2 Introduction 8 3 Expanding the frontiers of fundamental sciences 15 3.1 The Extreme Universe: Black Holes and Gravitational Waves 16 3.2 Dark Matter, Dark Energy and Large-Scale Structure 17 3.3 Galaxy and Structure Formation within Our Universe 18 3.4 Star and Planet Formation 19 3.5 Solar system magnetism 20 3.6 Stellar Hydrodynamics, Interstellar Medium, Astro-chemistry and Computational spectroscopy of exoplanets 21 3.7 Quantum ChromoDynamics (QCD) in extreme environments
    [Show full text]
  • IMPECCABLE: Integrated Modeling Pipeline for COVID Cure by Assessing Better Leads
    IMPECCABLE: Integrated Modeling PipelinE for COVID Cure by Assessing Better LEads Aymen Al Saadi1, Dario Alfe2,10, Yadu Babuji3, Agastya Bhati2, Ben Blaiszik3,4, Thomas Brettin4, Kyle Chard3,4, Ryan Chard3, Peter Coveney∗2,9, Anda Trifan4, Alex Brace4, Austin Clyde2, Ian Foster3,4, Tom Gibbs8, Shantenu Jha∗1,5, Kristopher Keipert8, Thorsten Kurth8, Dieter Kranzlmüller7, Hyungro Lee1, Zhuozhao Li3, Heng Ma4, Andre Merzky1, Gerald Mathias7, Alexander Partin4, Junqi Yin6, Arvind Ramanathan∗4, Ashka Shah4, Abraham Stern8, Rick Stevens∗3,4, Li Tan5, Mikhail Titov1, Aristeidis Tsaris6, Matteo Turilli1, Huub Van Dam5, Shunzhou Wan2, David Wifling7 1 Rutgers University, 2 University College London, 3 University of Chicago, 4 Argonne National Laboratory, 5 Brookhaven National Laboratory, 6 Oak Ridge Leadership Computing Facility, 7 Leibniz Supercomputing Centre, 8 NVIDIA Corporation, 9University of Amsterdam, 10University of Naples Federico II, ∗ Contact Authors Abstract Matteo Turilli1, Huub Van Dam5, Shunzhou Wan2, David Wifling7. 2020. The drug discovery process currently employed in the pharmaceu- IMPECCABLE: Integrated Modeling PipelinE for COVID Cure by Assess- tical industry typically requires about 10 years and $2-3 billion ing Better LEads. In Supercomputing ’20: International Conference for High to deliver one new drug. This is both too expensive and too slow, Performance Computing, Networking, Storage, and Analysis. ACM, New especially in emergencies like the COVID-19 pandemic. In silico York, NY, USA, 13 pages. https://doi.org/10.1145/1122445.1122456 methodologies need to be improved to better select lead compounds 1 Justification that can proceed to later stages of the drug discovery protocol accel- COVID-19 has claimed a million lives and resulted in over 35 mil- erating the entire process.
    [Show full text]
  • Chemistry Newsletter 2019
    UCL DEPARTMENT OF CHEMISTRY UCL Chemistry NEWSLETTER Contents Introduction by Head of Department I am feeling very relaxed as I start writing this welcome having 1. Introduction just returned from my honeymoon in Croatia after getting 2. Staff Highlights married in August! Being able to unwind after another busy and News year in the chemistry department, many highlights of which are included in this newsletter, was greatly appreciated. We were 3. Student Highlights pleased to see that UCL Chemistry moved up 11 places to 30th and News in the QS world university rankings by subject (from 41st in 2018). This was one of the biggest uplifts of any subject at UCL 4. Alumni Matters and puts us 4th in UK. 5. Research Highlights This academic year Professor Xiao Guo moved to the 6. Grants and Awards Department of Chemistry, University of Hong Kong after 11 years here at UCL. Farzana Hassain (Departmental 7. Publications Administrative Assistant) moved to a new role in Professor 8. Staff Jawwad Darr’s group. We welcomed Dr Yang Xu from the Technische Universitat Ilmenau as a Lecturer in Electrochemical Energy Storage, Dr Cally Haynes from University of Cambridge as a Lecturer in Organic Chemistry and Dr Anna Regoutz from Imperial College as a Lecturer in Materials Chemistry. In addition, Dr Adam Clancy and Dr Gi-Byoung Hwang will both be starting Ramsay Trust Fellowships in the department. We also welcomed Hannah Shalloe as our first Apprentice Technician, Helena Wong who has started as a Chemistry Teaching Laboratory Technician, Thom Dixon as our new Teaching and Learning (Student Lifecycle) administrator, Angelo Delbusso as our Workshop Technician and Malgorzata Puchnarewicz who has joined us as maternity cover for the mass spec facility.
    [Show full text]